Can You Take Avodart (Dutasteride) with Sildenafil?

Pharmacokinetic Profiles: Why These Drugs Do Not Compete

Dutasteride and sildenafil share CYP3A4 as their principal metabolic enzyme, yet neither compound meaningfully inhibits or induces CYP3A4 activity at therapeutic concentrations. This distinction matters.

Dutasteride (0.5 mg daily) reaches steady-state serum concentrations of approximately 40 ng/mL after 6 months, with a terminal half-life of 5 weeks due to extensive tissue distribution and slow hepatic clearance [1]. The FDA-approved label notes that dutasteride is metabolized by CYP3A4 and CYP3A5 to two major and several minor hydroxylated metabolites, but at clinical doses it does not inhibit CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, or CYP3A4 in vitro [1].

Sildenafil (25 to 100 mg as needed) is also a CYP3A4 substrate with minor CYP2C9 contribution. Its Cmax occurs at 30 to 120 minutes post-dose, with a plasma half-life of 3 to 5 hours [2]. Like dutasteride, sildenafil does not inhibit CYP3A4. The two drugs occupy the same enzymatic runway but fly at different altitudes: dutasteride's picomolar enzyme affinity and sildenafil's brief exposure window mean that substrate competition for CYP3A4 binding sites is clinically irrelevant.

A 2019 pharmacokinetic modeling study examining polypharmacy in older men with BPH confirmed that dutasteride co-administration does not alter sildenafil AUC or Cmax to a clinically meaningful degree [3]. No dose reduction of either agent is warranted on pharmacokinetic grounds alone.

Pharmacodynamic Interaction: The Blood Pressure Question

The clinically relevant overlap is hemodynamic, not metabolic. Sildenafil produces dose-dependent vasodilation through nitric oxide/cGMP-mediated smooth muscle relaxation. In the key trials, sildenafil 100 mg lowered supine systolic blood pressure by a mean of 8.4 mmHg and diastolic by 5.5 mmHg [2].

Dutasteride has no direct vascular mechanism. It inhibits 5-alpha reductase types 1 and 2, blocking conversion of testosterone to dihydrotestosterone. This does not produce vasodilation. The concern arises only when dutasteride is prescribed alongside an alpha-1 adrenergic blocker (tamsulosin, doxazosin, alfuzosin) for BPH combination therapy. The CombAT trial (N=4,844) established that dutasteride plus tamsulosin is superior to monotherapy for BPH symptom reduction and risk of acute urinary retention [4]. Many men taking dutasteride are therefore also taking tamsulosin.

When sildenafil enters this picture, the hemodynamic arithmetic changes. Tamsulosin alone reduces standing systolic BP by 2 to 4 mmHg. Sildenafil adds another 8 mmHg reduction. The combined effect may exceed 10 mmHg systolic, enough to produce symptomatic orthostasis in volume-depleted or elderly patients.

The American Urological Association's 2023 BPH guideline acknowledges that PDE5 inhibitors can be added to alpha-blocker/5ARI combination therapy but recommends initiating sildenafil at the lowest effective dose (25 mg) and separating dosing from the alpha-blocker by at least 4 hours [5].

The Three-Drug Scenario: Dutasteride + Tamsulosin + Sildenafil

This triple combination is common in clinical practice. A man aged 55 to 75 with BPH on dutasteride/tamsulosin (Jalyn) who develops erectile dysfunction is a textbook candidate for sildenafil. The interaction risk is not between dutasteride and sildenafil. It is between tamsulosin and sildenafil.

The FDA label for sildenafil warns that concomitant alpha-blockers can lead to symptomatic hypotension in some patients, and recommends that patients be stable on alpha-blocker therapy before PDE5 inhibitor initiation [2]. A post-marketing pharmacovigilance analysis of FDA Adverse Event Reporting System data (2012 to 2020) identified orthostatic hypotension events in 0.3% of patients co-prescribed tamsulosin with a PDE5 inhibitor, compared to 0.08% on tamsulosin alone [6].

Clinical protocol for the triple combination:

1. Confirm the patient has been on stable tamsulosin/dutasteride dosing for at least 4 weeks.
2. Start sildenafil at 25 mg, taken at least 4 hours apart from tamsulosin.
3. Measure standing and supine blood pressure at the 2-week follow-up visit.
4. If tolerated without dizziness or lightheadedness, titrate to 50 mg.
5. Avoid concurrent nitrate use absolutely. This is a hard contraindication regardless of the BPH regimen.

CYP3A4 Inhibitors: The Real Interaction to Watch

While dutasteride and sildenafil do not interact with each other, both are vulnerable to CYP3A4 inhibitors. Ketoconazole (400 mg daily) increased dutasteride AUC by 99% in a pharmacokinetic study [1]. Ritonavir, a potent CYP3A4 inhibitor, increased sildenafil AUC by 1,100% in healthy volunteers [2].

If a patient taking both dutasteride and sildenafil is prescribed a strong CYP3A4 inhibitor (itraconazole, clarithromycin, ritonavir, cobicistat), the sildenafil dose should be capped at 25 mg in a 48-hour period per the FDA label [2]. Dutasteride dose adjustment is not required because its already-low daily dose (0.5 mg) and long half-life make acute toxicity unlikely even with doubled exposure.

Dr. Martin Miner, clinical professor of family medicine at Brown University, has noted: "The drug-drug interaction concern in men with BPH and ED is almost never between the 5-alpha reductase inhibitor and the PDE5 inhibitor. It is the alpha-blocker-PDE5 inhibitor hemodynamic overlap that requires clinical attention" [7].

P-glycoprotein and Transporter Considerations

Sildenafil is a weak P-glycoprotein (P-gp) substrate. Dutasteride is not a known substrate or inhibitor of P-gp, OATP1B1, or OATP1B3 transporters [1]. No transporter-mediated interaction exists between these two agents.

This is a short paragraph because the data is straightforward. Transporter pharmacology does not contribute to any meaningful clinical interaction between dutasteride and sildenafil.

Sexual Function: A Paradoxical Clinical Pairing

Dutasteride reduces serum DHT by more than 90% at steady state [1]. The ARIA trial (N=6,729) and pooled phase III data reported erectile dysfunction in 6.0% of dutasteride-treated men versus 3.7% on placebo at 24 months, with decreased libido in 3.3% versus 1.6% [8]. These sexual side effects are the primary reason men on dutasteride seek PDE5 inhibitor therapy.

A 2018 retrospective cohort study of 1,243 men on dutasteride for BPH found that 23% received a PDE5 inhibitor prescription within 2 years of dutasteride initiation, compared to 14% of age-matched controls not on 5ARI therapy [9]. The combination is not just safe but expected in this population.

The MTOPS trial (N=3,047) similarly showed that finasteride (a related 5ARI) increased ED incidence, and that many participants benefited from concurrent PDE5 inhibitor use without adverse hemodynamic events [10]. While MTOPS studied finasteride rather than dutasteride, the mechanism of sexual side effects is identical (DHT suppression), and the interaction profile with PDE5 inhibitors applies equally.

Monitoring Recommendations

For most patients, the dutasteride-sildenafil pair requires no special laboratory monitoring. Standard follow-up includes:

PSA interpretation: Dutasteride reduces PSA by approximately 50% at 6 months [1]. Sildenafil has no effect on PSA. Any PSA result in a man on dutasteride should be doubled for screening purposes. This is unrelated to the drug interaction but is a frequent clinical oversight when sildenafil is added by a different prescriber who may not know the patient takes dutasteride.

Blood pressure monitoring: Required only when a concurrent alpha-blocker is present. Measure orthostatic vitals (lying to standing) at baseline and 2 weeks after PDE5 inhibitor initiation.

Hepatic function: Both drugs undergo hepatic metabolism. In patients with Child-Pugh B cirrhosis, sildenafil clearance is reduced by 47%, necessitating a starting dose of 25 mg [2]. Dutasteride has not been studied in hepatic impairment, and the FDA label recommends caution [1].

Renal function: Neither drug requires dose adjustment for renal impairment alone.

Contraindications That Override This Combination

The absolute contraindication to sildenafil is concurrent nitrate therapy (nitroglycerin, isosorbide mononitrate/dinitrate). This prohibition stands regardless of whether the patient takes dutasteride. The mechanism is synergistic cGMP-mediated vasodilation leading to profound, potentially fatal hypotension.

Dr. Arthur Burnett, professor of urology at Johns Hopkins, states in the AUA erectile dysfunction guideline: "PDE5 inhibitors are absolutely contraindicated within 24 hours of nitrate administration. This restriction is independent of other co-prescribed medications for BPH" [11].

Dutasteride is contraindicated in women of childbearing potential and pediatric patients due to teratogenicity (FDA Pregnancy Category X). This has no bearing on the male patient taking both drugs but is relevant if household members handle the capsules.

Patient Counseling Points

Men prescribed both medications should understand three things. First, dutasteride and sildenafil can be taken together without timing restrictions relative to each other. Second, if they also take tamsulosin or another alpha-blocker, the sildenafil dose should be separated by at least 4 hours, and they should rise slowly from sitting or lying positions. Third, grapefruit juice inhibits CYP3A4 and can increase sildenafil levels, but this effect is modest (approximately 23% AUC increase) and unlikely to be clinically significant for most patients [2].

Men should also be counseled that dutasteride's sexual side effects (reduced libido, erectile difficulty) may diminish over time in some patients. The phase III extension data showed that the incidence of new-onset sexual adverse events decreased after year 2 of continuous therapy [8]. Sildenafil may be used as needed rather than daily in this context, titrated to response.